文献速递精神分裂症与精神病性障碍

精神分裂症多基因评分与氯氮平处方剂量分层

Genomic Stratification of Clozapine Prescription Patterns Using Schizophrenia Polygenic Scores.
PubMed 文献 · Biol Psychiatry · 2022-08-05

研究在三个独立样本中检验精神分裂症多基因风险评分(PRS)与氯氮平治疗期间记录的最高剂量是否相关。校正人口学、药理学和临床协变量后,PRS 在 CLOZUK2、CLOZUK3 和挪威队列中均与最高氯氮平剂量相关,并与 >600 mg/天剂量相关。提示精神分裂症遗传易感性可能反映耐药性精神分裂症患者治疗决策相关因素。

要点

  • 精神分裂症 PRS 与氯氮平记录最高剂量在三个独立样本中均呈正相关。
  • 二次分析中 PRS 与使用 >600 mg/天氯氮平剂量相关。
  • 结果提示遗传易感性可能索引治疗决策相关因素,而非直接指导剂量。

核心结论

  • 精神分裂症 PRS 与氯氮平治疗中记录的最高剂量相关,提示遗传易感性可能索引耐药性精神分裂症患者的治疗决策因素。

研究设计与样本

  • 采用线性回归模型校正人口学、药理学和临床协变量,分析三个独立多 ancestry 样本:英国患者监测系统 CLOZUK2(n = 3133)、CLOZUK3(n = 909)和挪威治疗药物监测服务欧洲样本(n = 417)。
  • 二次分析合并两个英国队列,用 logistic 回归估计精神分裂症 PRS 与低、标准或高氯氮平剂量分类的关系。

主要发现

  • CLOZUK2 中精神分裂症 PRS 与记录最高氯氮平剂量相关(β = 12.22,SE = 3.78,p = .001)。
  • CLOZUK3 中相关(β = 12.73,SE = 5.99,p = .034)。
  • 挪威队列中相关(β = 46.45,SE = 18.83,p = .014)。
  • 二次分析中 PRS 与使用 >600 mg/天氯氮平剂量相关(odds ratio = 1.279,p = .006)。

关键数值与推荐

  • 氯氮平剂量分类为低、标准或高,高剂量阈值以 >600 mg/天定义。
  • PRS 与最高剂量关联的效应量按样本报告:CLOZUK2 β = 12.22,CLOZUK3 β = 12.73,挪威队列 β = 46.45。

临床怎么用

  • 在精准精神病学框架下,精神分裂症 PRS 可能作为氯氮平剂量决策的辅助参考,但当前证据不足以直接用于个体化剂量调整。
  • 临床解读氯氮平最高剂量时应综合考虑遗传与非遗传因素,PRS 仅提示与治疗决策相关的统计关联。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment-resistant schizophrenia affects approximately 30% of individuals with the disorder. Clozapine is the medication of choice in treatment-resistant schizophrenia, but optimizing administration and dose titration is complex. The identification of factors influencing clozapine prescription and response, including genetics, is of interest in a precision psychiatry framework. METHODS: We used linear regression models accounting for demographic, pharmacological, and clinical covariates to determine whether a polygenic risk score (PRS) for schizophrenia would be associated with the highest dose recorded during clozapine treatment. Analyses were performed across 2 independent multiancestry samples of individuals from a UK patient monitoring system, CLOZUK2 (n = 3133) and CLOZUK3 (n = 909), and a European sample from a Norwegian therapeutic drug monitoring service (n = 417). In a secondary analysis merging both UK cohorts, logistic regression models were used to estimate the relationship between schizophrenia PRSs and clozapine doses classified as low, standard, or high. RESULTS: After controlling for relevant covariates, the schizophrenia PRS was correlated with the highest clozapine dose on record for each individual across all samples: CLOZUK2 (β = 12.22, SE = 3.78, p = .001), CLOZUK3 (β = 12.73, SE = 5.99, p = .034), and the Norwegian cohort (β = 46.45, SE = 18.83, p = .014). In a secondary analysis, the schizophrenia PRS was associated with taking clozapine doses >600 mg/day (odds ratio = 1.279, p = .006). CONCLUSIONS: The schizophrenia PRS was associated with the highest clozapine dose prescribed for an individual in records from 3 independent samples, suggesting that the genetic liability for schizophrenia might index factors associated with therapeutic decisions in cohorts of patients with treatment-resistant schizophrenia.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kappel DB, Legge SE, Hubbard L, et al. Genomic Stratification of Clozapine Prescription Patterns Using Schizophrenia Polygenic Scores. Biol Psychiatry. 2022. PMID: 36244804. doi:10.1016/j.biopsych.2022.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。